Cargando…

Galectin-8 and -9 as prognostic factors for cervical cancer

PURPOSE: Galectins are carbohydrate-binding proteins with multiple effects on cell biology. Research shows that they play an important role in tumor development and progression. Therefore, in this study, the presence of Galectin-8 and -9 (Gal), both already known as prognostic factors in other tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Beyer, Susanne, Wehrmann, Maya, Meister, Sarah, Kolben, Theresa M., Trillsch, Fabian, Burges, Alexander, Czogalla, Bastian, Schmoeckel, Elisa, Mahner, Sven, Jeschke, Udo, Kolben, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470666/
https://www.ncbi.nlm.nih.gov/pubmed/35377045
http://dx.doi.org/10.1007/s00404-022-06449-9
_version_ 1784788894121721856
author Beyer, Susanne
Wehrmann, Maya
Meister, Sarah
Kolben, Theresa M.
Trillsch, Fabian
Burges, Alexander
Czogalla, Bastian
Schmoeckel, Elisa
Mahner, Sven
Jeschke, Udo
Kolben, Thomas
author_facet Beyer, Susanne
Wehrmann, Maya
Meister, Sarah
Kolben, Theresa M.
Trillsch, Fabian
Burges, Alexander
Czogalla, Bastian
Schmoeckel, Elisa
Mahner, Sven
Jeschke, Udo
Kolben, Thomas
author_sort Beyer, Susanne
collection PubMed
description PURPOSE: Galectins are carbohydrate-binding proteins with multiple effects on cell biology. Research shows that they play an important role in tumor development and progression. Therefore, in this study, the presence of Galectin-8 and -9 (Gal), both already known as prognostic factors in other tumor entities, were investigated in cervical cancer. Our aim was to examine the association of Gal-8 and -9 expression with histopathological markers and survival of the patients. METHODS: Gal-8 and -9 expression was investigated in 250 cervical cancer samples by immunohistochemistry. The staining was evaluated using the immunoreactive score (IRS). The results were correlated to clinical and pathological data. The correlation of Gal-8 and -9 expression with overall and relapse-free survival was analyzed. RESULTS: Expression of Gal-8 was associated with negative N-status and lower FIGO status. Detection of Gal-9 was connected to negative N-status and lower grading regarding all specimens. A correlation of Gal-9 with lower FIGO status was detected for squamous cell carcinoma (SCC) only. Expression of Gal-8 was associated with relapse-free survival of SCC patients in a positive manner. Gal-9 expression was associated with better overall survival. CONCLUSION: Our results suggest that expression of both galectins is inversely associated with tumor stage and progression. Gal-8 expression is associated with relapse-free survival of patients with SCC, while presence of Gal-9 in cervical cancer is associated with a better prognosis in regard of overall survival. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00404-022-06449-9.
format Online
Article
Text
id pubmed-9470666
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-94706662022-09-15 Galectin-8 and -9 as prognostic factors for cervical cancer Beyer, Susanne Wehrmann, Maya Meister, Sarah Kolben, Theresa M. Trillsch, Fabian Burges, Alexander Czogalla, Bastian Schmoeckel, Elisa Mahner, Sven Jeschke, Udo Kolben, Thomas Arch Gynecol Obstet Gynecologic Oncology PURPOSE: Galectins are carbohydrate-binding proteins with multiple effects on cell biology. Research shows that they play an important role in tumor development and progression. Therefore, in this study, the presence of Galectin-8 and -9 (Gal), both already known as prognostic factors in other tumor entities, were investigated in cervical cancer. Our aim was to examine the association of Gal-8 and -9 expression with histopathological markers and survival of the patients. METHODS: Gal-8 and -9 expression was investigated in 250 cervical cancer samples by immunohistochemistry. The staining was evaluated using the immunoreactive score (IRS). The results were correlated to clinical and pathological data. The correlation of Gal-8 and -9 expression with overall and relapse-free survival was analyzed. RESULTS: Expression of Gal-8 was associated with negative N-status and lower FIGO status. Detection of Gal-9 was connected to negative N-status and lower grading regarding all specimens. A correlation of Gal-9 with lower FIGO status was detected for squamous cell carcinoma (SCC) only. Expression of Gal-8 was associated with relapse-free survival of SCC patients in a positive manner. Gal-9 expression was associated with better overall survival. CONCLUSION: Our results suggest that expression of both galectins is inversely associated with tumor stage and progression. Gal-8 expression is associated with relapse-free survival of patients with SCC, while presence of Gal-9 in cervical cancer is associated with a better prognosis in regard of overall survival. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00404-022-06449-9. Springer Berlin Heidelberg 2022-04-04 2022 /pmc/articles/PMC9470666/ /pubmed/35377045 http://dx.doi.org/10.1007/s00404-022-06449-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Gynecologic Oncology
Beyer, Susanne
Wehrmann, Maya
Meister, Sarah
Kolben, Theresa M.
Trillsch, Fabian
Burges, Alexander
Czogalla, Bastian
Schmoeckel, Elisa
Mahner, Sven
Jeschke, Udo
Kolben, Thomas
Galectin-8 and -9 as prognostic factors for cervical cancer
title Galectin-8 and -9 as prognostic factors for cervical cancer
title_full Galectin-8 and -9 as prognostic factors for cervical cancer
title_fullStr Galectin-8 and -9 as prognostic factors for cervical cancer
title_full_unstemmed Galectin-8 and -9 as prognostic factors for cervical cancer
title_short Galectin-8 and -9 as prognostic factors for cervical cancer
title_sort galectin-8 and -9 as prognostic factors for cervical cancer
topic Gynecologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470666/
https://www.ncbi.nlm.nih.gov/pubmed/35377045
http://dx.doi.org/10.1007/s00404-022-06449-9
work_keys_str_mv AT beyersusanne galectin8and9asprognosticfactorsforcervicalcancer
AT wehrmannmaya galectin8and9asprognosticfactorsforcervicalcancer
AT meistersarah galectin8and9asprognosticfactorsforcervicalcancer
AT kolbentheresam galectin8and9asprognosticfactorsforcervicalcancer
AT trillschfabian galectin8and9asprognosticfactorsforcervicalcancer
AT burgesalexander galectin8and9asprognosticfactorsforcervicalcancer
AT czogallabastian galectin8and9asprognosticfactorsforcervicalcancer
AT schmoeckelelisa galectin8and9asprognosticfactorsforcervicalcancer
AT mahnersven galectin8and9asprognosticfactorsforcervicalcancer
AT jeschkeudo galectin8and9asprognosticfactorsforcervicalcancer
AT kolbenthomas galectin8and9asprognosticfactorsforcervicalcancer